In the last trading session, 5.26 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched 1.11. With the company’s per share price at $6.07 changed hands at -$0.1 or -1.62% during last session, the market valuation stood at $4.09B. IBRX’s last price was a discount, traded about -14.17% off its 52-week high of $6.93. The share price had its 52-week low at $1.25, which suggests the last value was 79.41% up since then. When we look at ImmunityBio Inc’s average trading volume, we note the 10-day average is 4.58 million shares, with the 3-month average coming to 3.97 million.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX was in red as seen at the end of in last trading. With action 18.32%, the performance over the past five days has been green. The drop to weekly highs of 6.78 subtracted -1.62% to the stock’s daily price. The company’s shares are showing year-to-date upside of 20.92%, with the 5-day performance at 18.32% in the green. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is 15.84% up. Looking at the short shares, we see there were 51.55 million shares sold at short interest cover period of 11.49 days.
ImmunityBio Inc (IBRX) estimates and forecasts
Data shows that the ImmunityBio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 271.25% over the past 6 months, a 31.31% in annual growth rate that is considerably higher than the industry average of 12.20%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for ImmunityBio Inc will rise 40.70%, while the growth in revenue is estimated to hit 46.90% for the next quarter. Year-over-year growth is forecast to reach 1,147.60% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $20k. 1 analysts are of the opinion that ImmunityBio Inc’s revenue for the quarter ending Jun 2024 will be $520k. The company’s revenue for the corresponding quarters a year ago was $360k and $41k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -94.40%. The estimates for the next quarter sales put growth at 1,168.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.17%.
IBRX Dividends
ImmunityBio Inc is expected to release its next quarterly earnings report between May 09 and May 13.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 79.62% of ImmunityBio Inc shares while 8.85% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 43.45%. There are 8.85% institutions holding the ImmunityBio Inc stock share, with Vanguard Group Inc the top institutional holder. As of Dec 30, 2023, the company held 1.98% of the shares, roughly 13.33 million IBRX shares worth $80.9 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 1.59% or 10.71 million shares worth $65.01 million as of Dec 30, 2023.
Among Mutual Funds, the top two as of Jan 30, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 6.46 million shares estimated at $39.22 million under it, the former controlled 0.96% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.63% of the shares, roughly 4.26 million shares worth around $25.83 million.
